# Phase 1 and Phase 2 Clinical Trials for Next-Generation Coronavirus Vaccines

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2024 · $15,048,720

## Abstract

The Objective of this task order supports NIAIDs goal to conduct a series of standardized phase 1 and phase 2 trials on next-generation vaccines to generate data to inform decisions on which candidate to advance.

## Key facts

- **NIH application ID:** 11042071
- **Project number:** 75N91019D00024-P00001-759102300008-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** KIRAN DATTA
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $15,048,720
- **Award type:** —
- **Project period:** 2023-06-01 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11042071

## Citation

> US National Institutes of Health, RePORTER application 11042071, Phase 1 and Phase 2 Clinical Trials for Next-Generation Coronavirus Vaccines (75N91019D00024-P00001-759102300008-1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/11042071. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*